GDTC · CytoMed Therapeutics Ltd
United States · RS rating 52 · As of 2026-11-03
| Price | 0.91 USD |
|---|---|
| 1-day change | +0.0% |
| RS rating (overall / 1M / 3M / 12M) | 52 / 35 / 80 / 17 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 22 / 24 / 15 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | – |
| Distance from 52-week high | +57.0% |
| Market cap (USD) | $12.0M |